drugset / Trial / NCT01249131

A Study of Relative Bioavailability and Food Effect Study of Cobimetinib in Healthy Participants

NCT01249131

Phase 1 Completed 20 enrolled Genentech, Inc.
RandomizedCrossoverOpen-labelBasic science

Summary

This study will be an open-label, randomized, 3-way, 6-sequence crossover study in healthy participants for determining the relative bioavailability of the tablet formulation to the capsule formulation and the effect of food on the relative bioavailability of the tablet formulation.

Timeline

Start
2010-12-01
Primary completion
2011-01-10
Completion
2011-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cobimetinib Small molecule 20 mg Oral

Indications

No indication recorded.